How can self-insured employers prepare for the portfolio impact of highcost gene therapies coming to market?

Joseph KnoxFoCUS, Research Briefs

Share the researchSelf-insured employers (SIEs) currently rely on traditional stop-loss insurance to protect against unexpected high-cost claims, including those for cell and gene therapies. Given that current approvals are in … Read More

Precision for Whom? Partnering with patients to ensure that Precision Medicine targets what matters

Joseph KnoxLEAPS, Research Briefs

Despite decades of growth and adaptation in patient engagement, knowing or being able to find guidance for whichmodel or approach will be most impactful in which healthcare or research context … Read More

Payer perspectives on outcomes tracking for value-based payment arrangements (VBPs)

Joseph KnoxFoCUS, Research Briefs

Share the researchWith the new CMS rule changing Medicaid Best Price reporting to encourage VBPs, many options are available for which healthcare system players will collect, protect and adjudicate the … Read More

The resource navigation challenges for patients and caregivers

Joseph KnoxFoCUS, Research Briefs

Share the researchWhile the problem of finding system-wide, implementable precision financing models for curative and durable therapies involves all stakeholders, patients and caregivers are directly affected by many different elements … Read More

Updated projection of US durable cell and gene therapies product-indication approvals based on December 2019 development pipeline

Joseph KnoxFoCUS, Research Briefs

Ongoing pipeline modeling by the MIT NEWDIGS FoCUS team projects 10X growth from July 2020 levels, but with large uncertainties. Download FoCUS Research Brief 2020F207v51Share the research

Downstream Innovation Part II

Joseph KnoxLEAPS, Research Briefs

December 2019 marked the transition from the LEAPS two-year design and feasibility assessment phase to the rollout of the rheumatoid arthritis in Massachusetts (RA MA) Pilot. Some important themes surrounding … Read More

Impact of FDA Guidelines on Communication between Developers and Payers on Metrics in Performance-Based Agreements

Joseph KnoxFoCUS, Research Briefs

The FDA regulates communications from pharmaceutical developers to ensure that statements about products are appropriately supported by evidence. In this Research Brief, we explore the possible impacts of these regulations … Read More

Precision Financing challenges for solid tumor adoptive T-cell therapies

Joseph KnoxFoCUS, Research Briefs

Durable gene and cell therapies represent a unique challenge to the US healthcare insurer/payer landscape, given the one-time treatment and associated high upfront cost but potentially durable outcomes. Previous research … Read More

Downstream Innovation Part I

enorman@mit.eduLEAPS, Research Briefs

There is a growing recognition of the importance of augmenting product- focused learning with disease-focused learning, incorporating the value of advances in real-world evidence (RWE). In LEAPS, we aim to … Read More

Tracking Medicaid Coverage of Durable Cell and Gene Therapies

Joseph KnoxFoCUS, Research Briefs

Durable cell and gene therapies represent a unique challenge to the US healthcare insurer/payer landscape, given the one-time treatment and associated high upfront cost but potentially durable outcomes. This study … Read More